SCHEMBL1923904

SCHEMBL1923904

CC(C)c1cc(C(=O)c2cccc(NC(=O)Nc3cccnc3)c2)c2c(N)ncnn12

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 4/20 0.83
▸ NTRK2 Q16620 5/20 0.77
▸ ALDH1A1 P00352 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ PDGFRB P09619 1/20 0.45
▸ POLB P06746 1/20 0.42
▸ P2RX4 Q99571 1/20 0.42
▸ AURKB Q96GD4 2/20 0.41
▸ AURKA O14965 1/20 0.41
▸ TAAR1 Q96RJ0 1/20 0.41
▸ EPHX2 P34913 1/20 0.41
▸ KDR P35968 3/20 0.41
▸ RET P07949 2/20 0.41
▸ BRAF P15056 1/20 0.41
▸ IKBKB O14920 1/20 0.40
▸ PDPK1 O15530 1/20 0.40
▸ EGFR P00533 1/20 0.40
▸ LCK P06239 1/20 0.40
▸ FYN P06241 1/20 0.40
▸ CDK1 P06493 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1925611 0.93 NTRK1 (0.71) NTRK1NTRK2ALDH1A1HTTPOLB
SCHEMBL1924684 0.91 NTRK1 (0.89) NTRK1NTRK2ALDH1A1PDGFRBAURKB
SCHEMBL1924757 0.91 NTRK1 (1.00) NTRK1NTRK2PDGFRBAURKBAURKA
SCHEMBL1924937 0.88 NTRK1 (0.88) NTRK1NTRK2PDGFRBAURKBAURKA
SCHEMBL1925208 0.88 NTRK1 (0.89) NTRK1NTRK2PDGFRBAURKBAURKA
SCHEMBL1924415 0.88 NTRK1 (0.86) NTRK1NTRK2PDGFRBPOLBAURKB
SCHEMBL1925471 0.88 NTRK1 (0.86) NTRK1NTRK2ALDH1A1HTTPDGFRB
SCHEMBL1924681 0.87 NTRK1 (0.85) NTRK1NTRK2PDGFRBAURKBAURKA
SCHEMBL1925131 0.87 NTRK2 (1.00) NTRK1NTRK2PDGFRBAURKBAURKA
SCHEMBL1925269 0.87 NTRK1 (0.88) NTRK1NTRK2PDGFRBAURKBAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1948664-B1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2011-06-08 — — EP claimed
US-7514435-B2 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-04-07 — — US claimed
US-20070149534-A1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-28 — — US claimed
EP-1948664-B1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2011-06-08 — — EP disclosed
US-7514435-B2 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-04-07 — — US disclosed
EP-1948664-A2 PYRROLOTRIAZINE KINASE INHIBITORS Brystol-Myers Squibb Company (US) 2008-07-30 — — EP disclosed
US-20070149534-A1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-28 — — US disclosed
WO-2007061882-A2 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149534-A1 PYRROLOTRIAZINE KINASE INHIBITORS NTRK2, NTRK3, NTRK1 NTRK1 3/4885NTRK2 1/4885ALDH1A1 2051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback